Market research
TRIL Trillium Therapeutics Inc
BATS USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.41
- Dividend yield
- 0.0%
- Beta
- 0.0
Profile
Instrument facts
- Exchange
- BATS
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA89620X5064
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.41
- Dividend yield
- 0.0%
- Beta
- 0.0
About
About Trillium Therapeutics Inc
Under normal circumstances, the fund will invest at least 80% of the fund"s net assets (plus borrowings for investment purposes) in Trillion Dollar Assets and/or financial instruments (such as options or swaps) that provide indirect exposure to Trillion Dollar Assets.
Research context
Trillium Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TRIL discussion.
5 years, 6 months ago
Trillium Therapeutics Inc is currently in a long term downtrend where the price is trading 25.7% below its 200 day moving average.
From a valuation standpoint, the stock is 363.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6202.2.
Trillium Therapeutics Inc's total revenue sank by 73.4% to $33K since the same quarter in the previous year.
Its net income has increased by 373.1% to $114M since the same quarter in the previous year.
Finally, its free cash flow fell by 9.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Trillium Therapeutics Inc gets an overall score of 1/5.